title: Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs.
abstract: The immune response-modifying drug Lektinol is a mistletoe preparation which is standardized with respect to bioactive viscum album agglutinin, the most active component of mistletoe. The present study was designed to evaluate the antimetastatic effects of this preparation following intravenous injection of B16 melanoma cells into mice. The standardized mistletoe extract was administered intravenously in doses of 100, 1000 or 5000 microliters/kg (equivalent to 3, 30 or 150 ng/kg of viscum album agglutinin) once daily for three weeks. An inhibition of mean pulmonary metastatic colonization of 58 to 95%, as measured by the number of melanoma cells on lung tissue slides, and a significant decrease of percentage of bronchoalveolar lavage pigmented cells were observed. In addition, a correlation of this antimetastatic activity with cellular immune parameters was investigated. In lavage fluids from the tumor-bearing mice, there was a 5 to 6-fold significant increase in the percentage of MAC-1+ (CD11b/CD18) immunocompetent macrophages in comparison with cells from vehicle-treated animals. The percentages of double-positive immature CD4+8+ thymocytes were significantly increased in animals treated with the standardized mistletoe extract. There were no signs of treatment-related toxicity. The results of this study indicate that the standardized mistletoe extract shows antimetastatic activity against B16 melanoma lung colonization.
authors.affiliation: RCC Research & Consulting Company Ltd., Itingen, Switzerland.
authors.forename: K
authors.initials: K
authors.lastname: Weber
authors.forename: U
authors.initials: U
authors.lastname: Mengs
authors.forename: T
authors.initials: T
authors.lastname: Schwarz
authors.forename: T
authors.initials: T
authors.lastname: Hajto
authors.forename: K
authors.initials: K
authors.lastname: Hostanska
authors.forename: T R
authors.initials: TR
authors.lastname: Allen
authors.forename: R
authors.initials: R
authors.lastname: Weyhenmeyer
authors.forename: H
authors.initials: H
authors.lastname: Lentzen
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D016516:CD4-CD8 Ratio; D002469:Cell Separation; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D014784:Mistletoe / Q000737:chemistry*; D009368:Neoplasm Transplantation; D008517:Phytotherapy; D028321:Plant Preparations; D010940:Plant Proteins; D010946:Plants, Medicinal; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological / Q000009:adverse effects / Q000627:therapeutic use*; D014183:Transplantation, Heterologous
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D028321:Plant Preparations; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; C009674:ribosome inactivating protein, Viscum